A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

NCT05680155 · Completed

Last updated 2026-05-28

This clinical trial is testing the drug XW003 in adults with type 2 diabetes to see how it affects blood sugar levels compared to a placebo.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 211 people

Who can join Ages 18–75 · all sexes

Timeline Started 2022-12 · est. completion 2024-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05680155 ↗

Description as written by the study sponsor.

The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone

Treatments tested

Ecnoglutide also known as XW003 Drug

Subcutaneous Injection
Placebo Drug

Subcutaneous Injection with matched volume

Main thing measured	Change from baseline in HbA1c
Sponsor	Hangzhou Sciwind Biosciences Co., Ltd.
Conditions studied	T2DM, Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05680155 ↗